p73 transcriptional activity increases upon cooperation between its spliced forms

被引:9
作者
Alarcon-Vargas, D
Fuchs, SY
Deb, S
Ronai, Z
机构
[1] CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA
[2] Wake Forest Univ, Ctr Comprehens Canc, Winston Salem, NC 27157 USA
关键词
p73; p53; Mdm2; gain of function; transcription;
D O I
10.1038/sj.onc.1203311
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The p53 homologue p73 efficiently activates p53-responsive genes. The well documented over-expression of p73 spliced forms in a wide variety of tumor types promoted us to elucidate the mechanisms underlying p73-mediated transcription. Using the luciferase reporter gene driven by Mdm2-minimal promoter in p53 null cells, we demonstrate that the weak transcriptional activity mediated by p73 alpha was increased by the mutant form p73 beta(292), which by itself is transcriptionally inactive. Similarly, cooperation between p73 beta and an inactive form of p73 alpha increased p73 beta-mediated transcriptional activities. Conversely, p73 beta elicited a silencing effect on a gain of function mutant, p53(281), which by itself mediated efficient transactivation of the MDR promoter. Neither anisomycin nor actinomycin D altered p73-mediated transcriptional activities, whereas sorbitol profoundly inhibited them through a rapid proteasome-dependent degradation of p73, Our observations point to plausible scenarios in which p73, through cooperation between p73 spliced forms and suppression of gain of function mutant p53 may elicit changes in the transcription of p53 target genes that play key roles in cell growth and death.
引用
收藏
页码:831 / 835
页数:5
相关论文
共 42 条
[1]   Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy [J].
Blandino, G ;
Levine, AJ ;
Oren, M .
ONCOGENE, 1999, 18 (02) :477-485
[2]   Two new p73 splice variants, γ and δ, with different transcriptional activity [J].
De Laurenzi, V ;
Costanzo, A ;
Barcaroli, D ;
Terrinoni, A ;
Falco, M ;
Annicchiarico-Petruzzeli, M ;
Levrero, M ;
Melino, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (09) :1763-1768
[3]  
Di Como CJ, 1999, MOL CELL BIOL, V19, P1438
[4]   GAIN OF FUNCTION MUTATIONS IN P53 [J].
DITTMER, D ;
PATI, S ;
ZAMBETTI, G ;
CHU, S ;
TERESKY, AK ;
MOORE, M ;
FINLAY, C ;
LEVINE, AJ .
NATURE GENETICS, 1993, 4 (01) :42-46
[5]   Inactivation of the p53-homologue p73 by the mdm2-oncoprotein [J].
Dobbelstein, M ;
Wienzek, S ;
König, C ;
Roth, J .
ONCOGENE, 1999, 18 (12) :2101-2106
[6]  
ELDIERY WS, 1993, CELL, V75, P817
[7]   Effects of p53 mutants derived from lung carcinomas on the p53-responsive element (p53RE) of the MDM2 gene [J].
Gorgoulis, VG ;
Zacharatos, PV ;
Manolis, E ;
Ikonomopoulos, JA ;
Damalas, A ;
Lamprinopoulos, C ;
Rassidakis, GZ ;
Zoumpourlis, V ;
Kotsinas, A ;
Rassidakis, AN ;
Halazonetis, TD ;
Kittas, C .
BRITISH JOURNAL OF CANCER, 1998, 77 (03) :374-384
[8]   An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control [J].
Gualberto, A ;
Aldape, K ;
Kozakiewicz, K .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (09) :5166-5171
[9]  
HANS S, 1999, EUR J SURG ONCOL, V25, P194
[10]   A MUTANT P53 TRANSGENE ACCELERATES TUMOR-DEVELOPMENT IN HETEROZYGOUS BUT NOT NULLIZYGOUS P53 DEFICIENT MICE [J].
HARVEY, M ;
VOGEL, H ;
MORRIS, D ;
BRADLEY, A ;
BERNSTEIN, A ;
DONEHOWER, LA .
NATURE GENETICS, 1995, 9 (03) :305-311